Search
The CEO of LH Capital, a key supporter of the life sciences industry in North Texas, describes the progress the biotech community here has made over the last year
Nicole Small discusses events that have recently taken place like the acquisition of Reata, ARPA-H choosing Dallas for a regional center,...
Oct 29, 2024
Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway
CFO Matthew Head describes the company's ON-BOARD platform and how they are not only developing therapeutics, but also an imaging product...
Oct 29, 2024
UT Southwestern professor Philipp Scherer talks about his work focusing on adipose cells and a local biotech company, PriveBio, that has come out of it
Dr. Scherer describes the work he is doing in areas like diabetes and fibro-inflammation. Plus, PriveBio's programs focusing on...
Oct 29, 2024
An investigator from MGH and the CSO of Inozyme discuss p1 data at Kidney Week showing that INZ-701 raised the levels of inorganic pyrophosphate, making it a possible treatment for calciphylaxis
Sagar Nigwekar and Yves Sabbagh describe the problem of calciphylaxis, and why they believe that raising the levels of PPi could have an...
Oct 27, 2024
Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego
Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...
Oct 27, 2024
Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech
Biotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies....
Oct 25, 2024
Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic diseases
CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key...
Oct 24, 2024
Transcriptional regulation in disease: opportunities, challenges, and the future
Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder...
Oct 24, 2024
A father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trial
Lauren Celano, a board member of the National Tay-Sachs & Allied Diseases Association, interviews Lee Greenwood about his family's...
Oct 23, 2024
Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more
Biren Amin joins BiotechTV from the NYSE and discusses BridgeBio, Ocular Therapeutix, Apellis, Sarepta, Solid Bio, Cargo Therapeutics,...
Oct 22, 2024
SecondWave Systems is using low intensity ultrasound to treat inflammatory conditions like RA
Co-Founder & CEO Anuj Bhardwaj describes the device SecondWave has developed and how it is designed to hit the spleen with ultrasound,...
Oct 21, 2024
San Diego based Libra Therapeutics is aiming to boost protein clearance in neurodegenerative diseases by targeting TRPML1
Chief Business Officer Isaac Veinbergs describes this approach and how Libra is focuses on ALS as a first indication.
Oct 21, 2024
Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better
Co-Founder and CEO Rida Mourtada describes how Lytica is adding a peptidic sequence to antibodies to improve their internalization into...
Oct 21, 2024
Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate
Founder & CEO Dori Thomas-Karyat describes why she believes a local delivery approach to the tumor is the solution to the shortcomings...
Oct 21, 2024
BioVenture VoiCes Episode 4: Enavate Sciences’ Sara Nayeem
Sara Nayeem describes her career path and how different firms she has worked for have had different approaches to investing. She...
Oct 21, 2024
Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare
Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and...
Oct 18, 2024
Entrepreneur Pierluigi Paracchi on San Raffaele, biotech in Italy, and his company Genenta Science
A leading voice in Italy's biotech community, he describes the world-class work that takes place at his home base of Ospedale San...
Oct 18, 2024
Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research
CEO Lisa Olson describes the IGFBP3/TMEM219 axis and the antibody Enthera has designed to target it, all of which are the result of...
Oct 17, 2024
The University of Chicago Biotechnology Association's leaders describe the events and career advancement tools that their club offers to those interested in biotech
President Busayo Bolonduro and steering committee members Joey Federico, Kasia Zawieracz, and Raven Moten describe academic and...
Oct 17, 2024
Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR
For this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the...
Oct 17, 2024
.png){kind=logo}
